API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
NUC-3373 (fosifloxuridine nafalbenamide), a new chemical entity derived from the nucleoside analog 5-fluorouracil, continues rapid development with multiple data readouts and dosing of first patients in Phase 3 colorectal cancer study.
Lead Product(s): Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area: Oncology Product Name: NUC-3373
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
10 patient out of 37 case studies highlighted NUC-3373’s ability to stabilize disease and achieve prolonged durations of progression-free survival. Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of therapy.
Lead Product(s): Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area: Oncology Product Name: NUC-3373
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021